Su Qiyuan, Hu Qian, Wu Songtao, Yang Suqin, Su Hanwen, Zhang Zhengjun, Ling Chengxiu
Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou, 215123, Jiangsu, People's Republic of China.
Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430016, Hubei, People's Republic of China.
Nat Prod Bioprospect. 2024 Dec 1;14(1):60. doi: 10.1007/s13659-024-00482-8.
This study aimed to evaluate the therapeutic properties of the traditional Chinese medicine Xuesanqi (XSQ, from the rhizome of Polygonum amplexicaule D. Don) in treating ulcerative colitis. We hypothesized that its many active components can alleviate symptoms of colitis by regulating the gut microbiota, its metabolites, and various signaling pathways. To test our hypotheses, we designed a DSS- induced colitis model in C57BL/6 male mice. Apparent metrics were evaluated in each group of mice and performed histological analysis of relevant tissues. The gut microbial composition was analyzed by 16S rRNA sequencing of bacteria. Simultaneously, the SCFAs content was detected by gas chromatography, inflammatory factor secretion was evaluated by ELISA or western-blot, the expression of tight junction protein and key proteins of the MAPK signaling pathway were analyzed by western-blot. Our result showed that the treatment with XSQ alleviated significant various symptoms such as weight loss, blood in stool, and shortening of colon. In addition, XSQ treatment restored the dysregulated gut microbiota in colitis mice, increased short chain fatty acids (SCFAs) and normalized the MAPK/ERK/JNK signaling pathways, promoted expression of tight junction protein Occludin, Claudin-1, and E-cadherin proteins. Furthermore, we also observed a dose-dependent pattern in these treatment responses. These findings demonstrated the active components of XSQ is a promising new treatment platform for ulcerative colitis.
本研究旨在评估中药血三七（XSQ，来源于蓼科植物何首乌的根茎）治疗溃疡性结肠炎的疗效。我们假设其多种活性成分可通过调节肠道微生物群、其代谢产物和各种信号通路来缓解结肠炎症状。为了验证我们的假设，我们在C57BL/6雄性小鼠中设计了一种DSS诱导的结肠炎模型。对每组小鼠的明显指标进行评估，并对相关组织进行组织学分析。通过细菌16S rRNA测序分析肠道微生物组成。同时，采用气相色谱法检测短链脂肪酸（SCFAs）含量，采用酶联免疫吸附试验（ELISA）或蛋白质免疫印迹法（western-blot）评估炎症因子分泌，采用蛋白质免疫印迹法分析紧密连接蛋白和MAPK信号通路关键蛋白的表达。我们的结果表明，XSQ治疗可显著缓解体重减轻、便血和结肠缩短等各种症状。此外，XSQ治疗可恢复结肠炎小鼠失调的肠道微生物群，增加短链脂肪酸（SCFAs），并使MAPK/ERK/JNK信号通路正常化，促进紧密连接蛋白Occludin、Claudin-1和E-钙黏蛋白的表达。此外，我们还观察到这些治疗反应呈剂量依赖性模式。这些发现表明，XSQ的活性成分是一种有前途的治疗溃疡性结肠炎的新平台。
